What is Arbutus Biopharma Corporation's EV / EBITDA?

Arbutus Biopharma Corporation (ABUS) reported EV / EBITDA of 5.5× in Q1 2026.

What does EV / EBITDA mean?

Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Arbutus Biopharma Corporation ABUS EV / EBITDA

EV / EBITDA at other companies

Arrowhead ResearchARWR

27.4×—

Gilead SciencesGILD

17.5×-0.7×

ALN

Alnylam PharmaceuticalsALNY

52.6×—

AnaptysBio, Inc.ANAB

32.6×—

Roivant SciencesROIV

1.8×—

Aurinia PharmaceuticalsAUPH

14×-8.7×

Other financials

Income statement

See full

Revenue$179.1M+10,055%

Operating income$168.9M+757%

Net income$169.7M+792%

EPS (diluted)$0.87+769%

Balance sheet

See full

Cash & equivalents$23.7M-36.1%

Total debt$631.0K-46.9%

Total equity$260.2M+229%

Total assets$277.2M+137%

Cash flow

See full

Operating cash flow-$8.1M+39.4%

CapEx--100%

Free cash flow-$4.7M+55.0%

Valuation

See full

Market cap$881.02M+34.1%

Enterprise value$857.94M+38.1%

P/E5.5×—

P/S4.6×-98.0×

Profitability

See full

Operating margin81.7%+42.1pp

Net margin84%+43.4pp

FCF margin-281.5%-119pp

Returns & leverage

See full

Return on equity94.7%+65.1pp

Debt / equity0×0.0×

Current ratio54.3×+48.3×

Where this comes from

Calculated from Arbutus Biopharma Corporation’s reported figures.

enterprise value/ebitda=5.5×

Based on the most recent quarter.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arbutus Biopharma Corporation's EV / EBITDA?: Arbutus Biopharma Corporation (ABUS) reported EV / EBITDA of 5.5× in Q1 2026.
What does EV / EBITDA mean?: Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.